260660 — Korea Arlico Pharm Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual cashflow statement for Korea Arlico Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	—	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	5,605	8,391	3,476	-6,174	-1,092
Depreciation
Amortisation
Non-Cash Items	1,068	1,908	-174	4,447	3,851
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-307	-8,570	-914	-13,459	2,315
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	8,967	4,836	7,148	-8,583	9,995
Capital Expenditures	-5,551	-21,735	-23,520	-3,680	-5,961
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-586	12,817	-3,730	8,514	3,325
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-6,137	-8,919	-27,250	4,834	-2,636
Financing Cash Flow Items	-56.3	19	0	-270	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	1,151	18,055	15,758	163	-3,522
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	4,013	13,876	-4,329	-3,582	3,828